VistaGen Therapeutics(US:VTGN) Globenewswire·2026-02-14 12:49Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's clinical trial results for fasedienol [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the March 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Vistagen [4]. - The complaint alleges that Vistagen's positive assertions regarding the success of fasedienol's clinical trials were false and misleading, leading to shareholders purchasing stock at artificially inflated prices [6][7]. Group 2: Clinical Trial Results - On December 17, 2025, Vistagen announced that its PALISADE-3 study for fasedienol failed to meet its primary efficacy endpoint, showing no statistically significant improvement in anxiety reduction compared to placebo [7]. - Following the announcement, Vistagen's stock price plummeted over 81%, opening at $0.88 per share [7]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to contact the firm [9].